Tejara Capital’s Arbutus Biopharma ABUS Stock Holding History

Tejara Capital’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-180,077	Closed	-$450K	–	76
2023 Q4	$450K	Hold	180,077	–	–	0.19%	55
2023 Q3	$366K	Hold	180,077	–	–	0.21%	57
2023 Q2	$414K	Sell	180,077 -19,923	-10%	-$51.9K	0.2%	61
2023 Q1	$606K	Hold	200,000	–	–	0.31%	57
2022 Q4	$466K	Buy	+200,000	New	+$478K	0.27%	68

Other funds holding ABUS

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

FCM

FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tejara Capital's ABUS Position: Q1 2024 in Review

Tejara Capital sold out of Arbutus Biopharma (ABUS) in Q1 2024, closing a stake of 180,077 shares — an estimated $450K sold.

Tejara Capital first reported a position in ABUS in Q4 2022 and held it in 5 quarters. The position peaked at $606K in Q1 2023. 119 funds tracked by Wall St. Rank hold ABUS as of Q1 2024.

Tejara Capital reported no remaining Arbutus Biopharma position as of Q1 2024 after selling out during the quarter.
Tejara Capital sold 180,077 Arbutus Biopharma shares in Q1 2024, an estimated $450K.
Tejara Capital first reported a position in Arbutus Biopharma in Q4 2022 and held it in 5 quarters.
Tejara Capital's Arbutus Biopharma position peaked at $606K in Q1 2023.
119 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2024.

Based on Tejara Capital's 13F filing for Q1 2024, filed 14 May 2024.